News
BioNTech, Bristol Myers and cancer immunotherapy
Digest more
Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...
With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...
The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...
The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...
Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...
A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback